| Overview |
| bs-2466R |
| Siglec 7 Polyclonal Antibody |
| ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human CD328/Siglec 7 |
| 401-467/467 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 27036 |
| Cell membrane |
| Sialic acid-binding Ig-like lectin 7; Adhesion inhibitory receptor molecule 1; Adhesion inhibitory receptor molecule 1, siglec-7; AIRM 1; AIRM1; CD328; CD328 antigen; CDw328; D siglec; D siglec precursor; P75; p75/AIRM1; QA79; QA79 membrane protein; Sialic acid binding Ig like lectin 7 precursor; Sialic acid binding immunoglobulin like lectin 7; SIGLEC7; SIGL7_HUMAN. |
| Siglec 7 is a member of the Siglec (sialic acid-binding immunoglobulin like lectin) subgroup of the immunoglobulin superfamily. Siglec 7 is able to mediate high levels of sialic acid-dependent binding to human erythrocytes and soluble sialoglycoconjugates. Addition of anti-Siglec 7 to haematopoietic cell cultures leads to reduced cell growth and prevents the development of dendritic cells. Predominantly expressed by resting and activated natural killer cells and at lower levels by granulocytes and monocytes. High expression can be found in tissues like the placenta, liver, lung, spleen, and peripheral blood leukocytes. |
| Application Dilution |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz